TNFSF11 Molekülinformation
Molecule Name
Tumor necrosis factor ligand superfamily member 11
Molekülalias
RANKL,CD254,TRANCE,OPGL,ODF
Drug Development Progress
Anzahl der klinischen Arzneimittel12
Anzahl der inverkehr gebrachten Arzneimittel19
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
Osteoclast differentiation factor，TRANCE，TNFSF11，TNF-related activation-induced cytokine，Tumor necrosis factor ligand superfamily member 11，CD254，TNF Superfamily Member 11，Osteoprotegerin Ligand，Receptor Activator Of Nuclear Factor Kappa B Ligand，Tumor Necrosis Factor Superfamily Member 11，ODF，RANKL，OPGL，CD254 Antigen，HRANKL2，TNLG6B，OPTB2，SOdf，RANK Ligand，Tumor Necrosis Factor (Ligand) Superfamily， Member 11，Receptor Activator Of Nuclear Factor Kappa-B Ligand，Tumor Necrosis Factor Ligand 6B
Molekülhintergrund
Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density. Some findings also suggestion some cancer cells, particularly prostate cancer cells, can activate an increase in bone remodeling and ultimately increase overall bone production.[17] This increase in bone remodeling and bone production increases the overall growth of bone metastasizes. The overall control of bone remodeling is regulated by the binding of RANKL with its receptor or its decoy receptor, respectively, RANK and OPG.
TNFSF11 Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Denosumab biosimilar(Shanghai Hansoh) | HS-20090; HS-20090-2 | Phase 3 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Bone Diseases; Bone metastases; Giant Cell Tumor of Bone; Hypercalcemia; Multiple Myeloma; Neoplasms; Nutritional and Metabolic Diseases; Osteoporosis, Postmenopausal; Solid tumours | Details |
| Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical) | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms; Osteoporosis, Postmenopausal | Details | |
| Denosumab biosimilar (GlycoNex) | SPD8; SPD-8 | Phase 3 Clinical | Glyconex Inc | Neoplasms; Osteoporosis | Details |
| Denosumab biosimilar (Hetero Biopharma) | Phase 3 Clinical | Hetero Biopharma Ltd | Solid tumours | Details | |
| Denosumab biosimilar(Curateq Biologics) | BP-16 | Phase 3 Clinical | CuraTeQ Biologics Pvt Ltd | Osteoporosis, Postmenopausal | Details |
| Recombinant anti-RANKL monoclonal antibody(Jiangsu Pacific-Meinuoke) | Phase 3 Clinical | Jiangsu Pacific Minok Biopharmaceutical Co., Ltd. | Osteoporosis, Postmenopausal | Details | |
| SHR-2017 | SHR-2017; SHR2017 | Phase 2 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd | Bone metastases; Multiple Myeloma; Osteoporosis; Solid tumours | Details |
| LZM-004 | LZM-004 | Phase 1 Clinical | Livzon(Group) Pharmaceutical Factory | Bone metastases | Details |
| Recombinant human anti-RANKL antibody (Innovent Biologics) | IBI-307 | Phase 1 Clinical | Osteoporosis | Details | |
| GB-223 | GB-223; GB223 | Phase 1 Clinical | Genor Biopharma Co Ltd | Bone metastases; Bone Neoplasms; Giant Cell Tumor of Bone; Osteoporosis, Postmenopausal; Solid tumours | Details |
| Denosumab biosimilar (Kpc Pharmaceuticals) | MV-088 | Phase 1 Clinical | Kpc Pharmaceuticals Inc | Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar (Zhejiang Hisun) | HS629 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Bone metastases; Solid tumours | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Denosumab biosimilar (Teva Pharmaceutical) | TVB-009P; TVB-009 | Approved | Teva Pharmaceutical Industries Ltd | PONLIMSI, DEGEVMA | EU | Bone Resorption; Osteoporosis, Postmenopausal; Osteoporosis; Giant Cell Tumor of Bone; Neoplasms, Bone Tissue | Teva Gmbh | 2025-11-17 | Bone Neoplasms; Bone Resorption; Giant Cell Tumor of Bone; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar (Henlius) | HLX14; HLX-14 | Approved | Bilprevda, Bildyos | United States | Hypercalcemia; Giant Cell Tumors; Bone metastases; Osteoporosis, Postmenopausal | Shanghai Henlius Biotech Inc | 2025-08-29 | Arthritis, Rheumatoid; Bone metastases; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Fractures, Bone; Giant Cell Tumor of Bone; Giant Cell Tumors; Glucocorticoid-induced osteoporosis; Hypercalcemia; Multiple Myeloma; Neoplasm Metastasis; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal; Prostatic Neoplasms | Details | |
| Narlumosbart | JMT-103 | Approved | Shanghai Jmt-Bio Inc | 津立泰, 津立生 | Mainland China | Giant Cell Tumor of Bone | Shanghai Jmt-Bio Inc | 2023-09-05 | Bone Diseases; Bone metastases; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis; Hypercalcemia; Multiple Myeloma; Neoplasms; Osteoporosis; Osteoporosis, Postmenopausal; Solid tumours | Details |
| Denosumab biosimilar (Mabwell) | 9-MW-0311; 9MW0321; 9-MW0321; 9MW-0321; 9-MW-0321; TK-006; MW-032; MW-031; 9MW0311; 9-MW0311; 9MW-0311 | Approved | Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd | 迈利舒, 迈卫健, MAIWEIJIAN, MAILISHU | Mainland China | Osteoporosis, Postmenopausal | Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd | 2023-03-28 | Bone metastases; Bone Neoplasms; Breast Neoplasms; Giant Cell Tumor of Bone; Osteoporosis; Osteoporosis, Postmenopausal; Solid tumours | Details |
| Denosumab biosimilar (Qilu Pharma) | QL-1206 | Approved | Qilu Pharmaceutical Co Ltd | 鲁可欣 | Mainland China | Osteoporosis, Postmenopausal | Qilu Pharmaceutical Co Ltd | 2023-09-28 | Bone metastases; Giant Cell Tumor of Bone; Osteoporosis, Postmenopausal; Solid tumours | Details |
| Denosumab biosimilar (Boan Biopharma/Luye) | LY-01011; BA-1102; BA-6101; LY-06006 | Approved | Shandong Boan Biotechnology Co Ltd | 博洛加, Boluojia, Boyoubei, 博优倍 | Mainland China | Osteoporosis, Postmenopausal | Shandong Boan Biotechnology Co Ltd | 2022-11-08 | Bone metastases; Bone Neoplasms; Giant Cell Tumor of Bone; Neoplasm Metastasis; Neoplasms; Osteoporosis; Osteoporosis, Postmenopausal; Solid tumours | Details |
| Denosumab biosimilar (Accord Healthcare) | Approved | Accord Healthcare Slu | Jubereq, Osvyrti | EU | Osteoporosis; Neoplasms, Bone Tissue; Giant Cell Tumor of Bone; Bone Resorption; Osteoporosis, Postmenopausal | Accord Healthcare Slu | 2025-05-26 | Bone metastases; Bone Resorption; Giant Cell Tumor of Bone; Hypercalcemia; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal | Details | |
| Denosumab | NSC-744010; AMG-162 | Approved | Amgen Inc | Prolia, Xgeva, Pralia, Ranmark, 普罗力 | EU | Osteoporosis, Postmenopausal | Amgen Europe Bv | 2010-05-26 | Anorexia Nervosa; Arthritis, Rheumatoid; Arthropathy, Neurogenic; Bone Cysts, Aneurysmal; Bone Diseases; Bone Diseases, Metabolic; Bone metastases; Bone Neoplasms; Breast Diseases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Cataract; Chondroblastoma; Colonic Neoplasms; Crohn Disease; Endocrine Gland Neoplasms; Feeding and Eating Disorders; Fibroma; Fibrous Dysplasia of Bone; Fractures, Bone; Giant Cell Tumor of Bone; Giant Cell Tumors; Glucocorticoid-induced osteoporosis; Granuloma, Giant Cell; Head and Neck Neoplasms; Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypercalcemia; Kidney Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Osteoarthritis; Osteoarthritis, Knee; Osteoblastoma; Osteogenesis Imperfecta; Osteoporosis; Osteoporosis | Details |
| Denosumab biosimilar(Enzene Biosciences) | ENZ-215 | Approved | Enzene Biosciences Ltd | Osqay | EU | Bone Resorption | Theramex Ireland Ltd | 2026-01-08 | Bone Resorption; Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar (Alvotech Swiss) | AVT-03; AVT03 | Approved | Alvotech Swiss Ag | Acvybra, Xbonzy | EU | Giant Cell Tumor of Bone; Osteoporosis, Postmenopausal; Bone Resorption; Neoplasms, Bone Tissue; Osteoporosis | Stada Arzneimittel Ag, Reddy Holding Gmbh | 2025-11-17 | Bone Resorption; Giant Cell Tumor of Bone; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar(Mabxience) | MB-09 | Approved | Mabxience Sa | Zadenvi, Izamby, Enwylma, Denbrayce | EU | Neoplasms, Bone Tissue; Bone Resorption; Osteoporosis, Postmenopausal; Osteoporosis; Giant Cell Tumor of Bone | Zentiva Ks, Mabxience Research SL | 2025-06-26 | Bone Diseases; Bone Resorption; Fractures, Bone; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis; Hypercalcemia; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar (Biocon Biologics) | Bmab-1000 | Approved | Biocon Ltd | Vevzuo, Evfraxy | EU | Neoplasms, Bone Tissue; Giant Cell Tumor of Bone | Biosimilar Collaborations Ireland Ltd | 2025-06-25 | Bone metastases; Bone Resorption; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal; Prostatic Neoplasms | Details |
| Denosumab biosimilar(Reliance Life Sciences) | R-TPR-045 | Approved | Reliance Life Sciences | DenosuRel | India | Osteoporosis, Postmenopausal; Bone metastases | Reliance Life Sciences | 2022-02-01 | Bone metastases; Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar (Gedeon Richter) | RGB-14-P | Approved | Gedeon Richter Plc | ENOBY, XTRENBO, Yaxwer, Junod | EU | Bone Resorption; Osteoporosis, Postmenopausal; Osteoporosis; Giant Cell Tumor of Bone; Neoplasms, Bone Tissue | Gedeon Richter Plc | 2025-06-23 | Bone metastases; Bone Resorption; Breast Neoplasms; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal; Prostatic Neoplasms | Details |
| Denosumab biosimilar(Fresenius Kabi) | FKS-518 | Approved | Fresenius Kabi Swissbiosim Gmbh | BOMYNTRA, CONEXXENCE | United States | Giant Cell Tumor of Bone; Hypercalcemia; Bone metastases | Fresenius Kabi Usa Llc | 2025-03-25 | Bone metastases; Bone Resorption; Giant Cell Tumor of Bone; Hypercalcemia; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar (Samsung Bioepis) | SB-16 | Approved | Samsung Bioepis Co Ltd | Ospomyv, Xbryk, XBRYK, OBODENCE | EU | Neoplasms, Bone Tissue; Giant Cell Tumor of Bone; Bone Resorption; Osteoporosis; Osteoporosis, Postmenopausal | Samsung Bioepis Nl Bv | 2025-02-12 | Bone Resorption; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar (Celltrion) | CT-P41 | Approved | Celltrion Inc | Stoboclo, Osenvelt | EU | Bone Resorption; Osteoporosis, Postmenopausal; Osteoporosis; Neoplasms, Bone Tissue; Giant Cell Tumor of Bone | Celltrion Healthcare Hungary Kft | 2025-02-14 | Bone Resorption; Breast Neoplasms; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal; Prostatic Neoplasms | Details |
| Denosumab biosimilar (Sandoz) | GP-2411 | Approved | Novartis Pharma Ag, Sandoz | Jubbonti®, Wyost® | United States | Osteoporosis, Postmenopausal; Osteoporosis; Glucocorticoid-induced osteoporosis | Sandoz, Sandoz Inc | 2024-03-05 | Bone Resorption; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis; Neoplasms, Bone Tissue; Osteoporosis; Osteoporosis, Postmenopausal | Details |
| Denosumab biosimilar (Alphamab) | KN-012 | Approved | Suzhou Alphamab Co Ltd | Mainland China | Osteoporosis, Postmenopausal | Philippine Biological Technology (Jilin) Co Ltd, Alphamab Jilin Co Ltd | 2024-09-03 | Osteoporosis, Postmenopausal | Details |